In Brief: LaserSight
This article was originally published in The Gray Sheet
LaserSight: Acquires worldwide distribution rights to the Ruiz disposable microkeratome, an instrument used to create the corneal flap in laser in situ keratomileusis (LASIK) procedures, the St. Louis firm says. The company expects to begin international sales "late this year or early next year" at a price of approximately $7,500; a disposable component used with the device is priced at $125. A 510(k) will be submitted to FDA in the next few weeks for the device. Under the terms of the deal, LaserSight paid $400,000 in cash and supplied one LaserScan LSX scanning excimer laser to the instrument's inventors, Luis Antonio Ruiz, MD, and Sergio Lenchig of Bogota, Colombia; two additional payments of $150,000 each will be made six and 12 months after the initial shipment date...
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.